OncoSolutions Taps CollabRx to Provide Variant Interpretation Services | GenomeWeb

NEW YORK (GenomeWeb) – CollabRx said this week that Singapore-based private oncology firm OncoSolutions Cancer Center has signed a multi-year agreement to use CollabRx's Genetic Variant Annotation (GVA) service to analyze tumor genetic data.

The OncoSolutions deal is CollabRx's "first such commercial relationship with a private oncology company," Thomas Mika, chairman, president and CEO of CollabRx, noted in a statement. He added the agreement also expands the company's presence in Asia.

Financial and other terms of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.